Tangerine Holdings Limited – Trademark Portfolio
Entity Type: 16
Tangerine Holdings Limited holds 12 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 12 filings in this category. The portfolio also extends into Class 31 (Natural Agricultural Products) across 2 Nice Classification classes. Currently, 8 trademarks are registered. Notable registered marks include LYPEX, COATEX, CYSTAID, KAMINOX, and SAMYLIN. The owner is based in Lytham St. Annes.
"Docklands", Dock Road
Lytham St. Annes FY85AQ , GB
Showing of trademarks Trademarks
Trademark Classifications
Tangerine Holdings Limited's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Raw and unprocessed agricultural, aquacultural, horticultural and forestry products
Frequently Asked Questions
How many trademarks does Tangerine Holdings Limited have?
Tangerine Holdings Limited has 12 U.S. trademarks filed with the USPTO. Of these, 8 registered, 2 abandoned, 2 cancelled.
What trademark classes does Tangerine Holdings Limited file in?
Tangerine Holdings Limited files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 31 (Natural Agricultural Products). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Tangerine Holdings Limited's most well-known trademarks?
Tangerine Holdings Limited's registered trademark portfolio includes well-known marks such as LYPEX, COATEX, CYSTAID, KAMINOX, and SAMYLIN. These are among 8 currently registered trademarks in the portfolio.
What is Tangerine Holdings Limited's trademark registration success rate?
Tangerine Holdings Limited has a 67% trademark registration rate, with 8 out of 12 resolved applications resulting in successful registration. Currently, 0 applications are pending review.